居里

CRIS NASDAQ
1.700
+0.070
+4.29%
交易中 14:12 06/25 EDT
开盘
1.670
昨收
1.630
最高
1.720
最低
1.640
成交量
8.27万
成交均量(3M)
56.47万
52周最高
2.650
52周最低
0.6000
换手率
0.25%
市值
5,635.63万
分时
5日
1月
3月
1年
5年

相关股票

微牛行情栏目提供居里 CRIS股票价格,居里股票实时行情,公司简介,财报信息,股本结构等,掌握美港股行情走势,开盘价,收盘价,总市值,换手率,市盈率,收益率等数据,及时把握美股港股投资机会。

公司介绍

Curis, Inc. is a biotechnology company seeking to develop and commercialize drug candidates for the treatment of cancers. The Company's drug candidate is CUDC-907, an orally-available, small molecule inhibitor of histone deacetylase (HDAC) and phosphatidylinositol-3-kinase (PI3K) enzymes. CUDC-907 is an oral, dual inhibitor of Class I and II HDAC, as well as Class I PI3K enzymes. CA-170 is an oral small molecule drug candidate that is designed to selectively target programmed death ligand-1 (PDL1) and V-domain Ig suppressor of T-cell activation (VISTA) immune checkpoint proteins, both of which independently function as negative regulators of immune activation. CA-4948 is an oral small molecule drug candidate that is designed to inhibit the Interleukin-1 receptor-associated kinase 4 (IRAK4) kinase, which is a transducer of toll-like receptor or certain interleukin receptor signaling pathways.
展开 >

最近浏览

名称
价格
涨跌幅